Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Income from Continuing Operations (2016 - 2025)

Cytokinetics (CYTK) has disclosed Income from Continuing Operations for 16 consecutive years, with 233514000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations changed N/A to 233514000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 681778000.0, a N/A change, with the full-year FY2025 number at 657837000.0, down 14.62% from a year prior.
  • Income from Continuing Operations was 233514000.0 for Q4 2025 at Cytokinetics, down from 155631000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 13681000.0 in Q2 2022 to a low of 233514000.0 in Q4 2025.
  • A 5-year average of 110940941.18 and a median of 129401000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 6173.01% in 2021, then surged 76.76% in 2022.
  • Cytokinetics' Income from Continuing Operations stood at 25922000.0 in 2021, then plummeted by 417.27% to 134087000.0 in 2022, then dropped by 0.37% to 134582000.0 in 2023, then fell by 11.25% to 149729000.0 in 2024, then crashed by 55.96% to 233514000.0 in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Income from Continuing Operations are 233514000.0 (Q4 2025), 155631000.0 (Q1 2025), and 149729000.0 (Q3 2024).